FDA — authorised 30 November 1979
- Application: NDA018144
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: CENTRAX
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Prazene in United States
FDA authorised Prazene on 30 November 1979
Marketing authorisations
FDA
- Status: approved
FDA
- Application: ANDA070427
- Marketing authorisation holder: USL PHARMA
- Local brand name: PRAZEPAM
- Indication: CAPSULE — ORAL
- Status: approved
FDA
- Application: ANDA070428
- Marketing authorisation holder: USL PHARMA
- Local brand name: PRAZEPAM
- Indication: CAPSULE — ORAL
- Status: approved
FDA
- Application: NDA017415
- Marketing authorisation holder: PARKE DAVIS
- Local brand name: CENTRAX
- Indication: TABLET — ORAL
- Status: approved
Other Neuroscience approved in United States
Frequently asked questions
Is Prazene approved in United States?
Yes. FDA authorised it on 30 November 1979; FDA has authorised it; FDA has authorised it.
Who is the marketing authorisation holder for Prazene in United States?
PARKE DAVIS holds the US marketing authorisation.